Anticoagulation

1
Pipeline Programs
4
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

CSL Behring
CSL BehringIL - Bradley
1 program
1
four factor prothrombin complex concentratePhase 41 trial
Active Trials
NCT03473132Unknown50Est. Mar 2022
Bristol Myers Squibb
1 program
Real-World Evidence of Anticoagulation Treatment In Non-Valvular Atrial Fibrillation In ItalyN/A1 trial
Active Trials
NCT02921126Completed9,914Est. Aug 2018
Pfizer
PfizerNEW YORK, NY
1 program
Real-World Evidence of Anticoagulation Treatment In Non-Valvular Atrial Fibrillation In ItalyN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
CSL Behringfour factor prothrombin complex concentrate
Bristol Myers SquibbReal-World Evidence of Anticoagulation Treatment In Non-Valvular Atrial Fibrillation In Italy

Clinical Trials (2)

Total enrollment: 9,964 patients across 2 trials

NCT03473132CSL Behringfour factor prothrombin complex concentrate

Assessment of Coagulation Factor Levels in Left Ventricular Device (LVAD )Patients Following Temporary Warfarin Reversal With Four Factor Prothrombin Complex Concentrate (4F-PCC)

Start: Mar 2018Est. completion: Mar 202250 patients
Phase 4Unknown
NCT02921126Bristol Myers SquibbReal-World Evidence of Anticoagulation Treatment In Non-Valvular Atrial Fibrillation In Italy

Real-World Evidence of Anticoagulation Treatment In Non-Valvular Atrial Fibrillation In Italy

Start: Apr 2017Est. completion: Aug 20189,914 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 companies competing in this space